Edition:
United Kingdom

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

6.16USD
19 Oct 2018
Change (% chg)

$0.29 (+4.94%)
Prev Close
$5.87
Open
$5.89
Day's High
$6.20
Day's Low
$5.89
Volume
8,576
Avg. Vol
15,658
52-wk High
$12.36
52-wk Low
$5.25

Latest Key Developments (Source: Significant Developments)

Ovid Therapeutics Files For Mixed Shelf Of Up To $200 Mln
Friday, 1 Jun 2018 

June 1 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING.  Full Article

Ovid Therapeutics Reports Q1 Loss Per Share Of $0.54
Tuesday, 8 May 2018 

May 8 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE PROGRESS.Q1 LOSS PER SHARE $0.54.Q1 EARNINGS PER SHARE VIEW $-0.52 -- THOMSON REUTERS I/B/E/S.  Full Article

Ovid Therapeutics Reports Q4 Loss Per Share $0.45
Thursday, 29 Mar 2018 

March 29 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS.Q4 LOSS PER SHARE $0.45.Q4 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.OVID THERAPEUTICS - PLAN TO INITIATE PHASE 2 CLINICAL TRIAL WITH OV101 FOR TREATMENT OF ADOLESCENTS AND YOUNG ADULTS WITH FRAGILE X SYNDROME IN 2018.TOPLINE DATA FOR PHASE 1B/2A CLINICAL TRIAL OF TAK-935/OV935 EXPECTED IN SECOND HALF 2018.  Full Article

Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME.OVID THERAPEUTICS INC - CURRENTLY EVALUATING PHASE 1B/2A CLINICAL TRIAL OF TAK-935/OV935 WITH DATA ANTICIPATED IN 2018.  Full Article

Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME.OVID THERAPEUTICS INC - EXPANDED ONGOING PHASE 2 STARS CLINICAL TRIAL TO INCLUDE BOTH ADULTS AND ADOLESCENTS WITH ANGELMAN SYNDROME.OVID THERAPEUTICS INC - EXPECTS DATA FROM STARS TRIAL IN SECOND HALF OF 2018.  Full Article

Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME.OVID THERAPEUTICS INC - HAVE RAPIDLY ADVANCED TAK-935/OV935 PROGRAM INTO A PHASE 1B/2A CLINICAL TRIAL AND ANTICIPATE DATA IN 2018.  Full Article

Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients
Tuesday, 28 Nov 2017 

Nov 28 (Reuters) - Ovid Therapeutics Inc ::OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS.OVID THERAPEUTICS INC - ‍ANTICIPATES DATA FROM STARS TRIAL TO BE AVAILABLE IN SECOND HALF OF 2018​.OVID THERAPEUTICS INC - ‍RESULTS FROM PHASE 1 CLINICAL TRIAL OF ADOLESCENTS WITH ANGELMAN AND FRAGILE X SYNDROMES DEMONSTRATED OV101 WAS WELL TOLERATED​.OVID THERAPEUTICS INC - ‍IN TRIAL, OV101 WAS FOUND TO BE GENERALLY SAFE AND WELL TOLERATED​.  Full Article

Ovid Therapeutics Q3 loss per share $0.38
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Ovid Therapeutics Inc ::Ovid Therapeutics reports third quarter 2017 financial results and corporate progress.Q3 loss per share $0.38.Q3 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S.Ovid Therapeutics Inc - ‍cash and cash equivalents $96 million as at Sept 30 , 2017 versus $51.9 million as at Dec 31, 2016​.  Full Article

Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Ovid Therapeutics Inc :Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935/OV935 in adults with rare epilepsies.  Full Article

Ovid Therapeutics Q1 loss per share $3.48
Tuesday, 13 Jun 2017 

June 13 (Reuters) - Ovid Therapeutics Inc ::Ovid Therapeutics reports first quarter 2017 financial results and recent corporate progress.Q1 loss per share $3.48.Q1 earnings per share view $-0.87 -- Thomson Reuters I/B/E/S.Ovid Therapeutics Inc says company expects topline data to evaluate ov101 to be available in second half of 2017..  Full Article

BRIEF-Ovid Therapeutics Reports Q1 Loss Per Share Of $0.54

* OVID THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND CORPORATE PROGRESS